Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.
about
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsImmune Infiltration and Prostate CancerNovel targeted therapeutics for metastatic castration-resistant prostate cancer.Prostate cancer and inflammation: the evidence.Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor typesElevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer.Prostate cancer immunotherapy.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Differential patterns of large tumor antigen-specific immune responsiveness in patients with BK polyomavirus-positive prostate cancer or benign prostatic hyperplasiaBlocking immune checkpoints in prostate, kidney, and urothelial cancer: An overviewKey genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial.Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy.Immunotherapy for prostate cancer: an emerging treatment modality.The dual role of the X-linked FoxP3 gene in human cancersImmunotherapy of prostate cancer: identification of new treatments and targets for therapy, and role of WAP domain-containing proteins.Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy.Blood cells and their use in active immunotherapy of prostate cancer.Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.Immune response to sipuleucel-T in prostate cancerCellular and molecular mechanisms in cancer immune escape: a comprehensive review.Polyomavirus BK and prostate cancer: a complex interaction of potential clinical relevance.Regulation of prostate cancer progression by the tumor microenvironment.Cellular determinants and microenvironmental regulation of prostate cancer metastasis.Oncolytic virotherapy for urological cancers.Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade.Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling.Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer.Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression.Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue.The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.The inflammatory microenvironment and microbiome in prostate cancer development.FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer.Immunotherapy for Prostate Cancer: Where We Are Headed.Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls.Characterization of the T-cell receptor repertoire by deep T cell receptor sequencing in tissues from patients with prostate cancer.
P2860
Q26740601-8C2E2630-43C9-4878-B175-FF07A707B58DQ26750672-9A339AE5-1EA3-4AF5-A27B-2235B72D0B66Q26798412-25C2F92B-EE46-4C4A-A17F-AD61833DEE75Q33642278-2A4DA38A-7E46-47CD-B275-CC79014FB973Q33642321-E0D600F1-1951-485F-997A-0FCCA20FB77DQ34445730-7C210339-1668-407A-8CB0-A4EB866CADE9Q34577158-14ED6756-A3E9-4E55-A611-6C4706F11EB9Q34669751-8F08573C-F307-4009-B09A-454DBF6830AAQ35318562-71F40549-6593-4B34-8761-F7A4EC9DE066Q35688425-DF93A5D2-56B8-4105-95FE-9E4A67308135Q35980893-8F7661D2-101A-46FA-862C-6C32228DA63EQ36172036-B89AD4E7-204E-4EF9-8515-57ED43F2E4F7Q36806906-62106A91-B3CC-4112-8A18-FD6AA3281CE5Q36827156-04C6AA40-5478-4A10-B0B2-92A15DA644B6Q37435472-2CB49322-86CF-486A-BFC7-C5A378397612Q37443603-4C40301E-1ADE-4594-888C-0C13A4E6F529Q37676065-CEF2B341-3C12-485D-9149-AC17A6EE403BQ37691634-FB22DFDA-715A-410C-9C2D-CB67A2E5A0A8Q37864831-CE33C0E7-8217-4CF9-A931-A7E027B1432AQ37936540-8434EB0E-5CCB-438A-B3AA-98D25F74A2C7Q37983730-B0173AD8-E070-4AD7-8D87-AECD25C9DA83Q37988722-E6956449-0EFB-4AA2-9FBF-B744BB88EDECQ38069512-0108A2B2-EEA5-4939-8564-B139764C0E22Q38161390-95C143A8-1208-46AC-9726-8AD1677A1340Q38170150-678AFFA9-5297-45EB-B8DB-1ACB504CD131Q38574112-7BF94B58-8E62-4632-AED6-4744414AF1F9Q38717262-9868C9DA-FEC4-42E6-ACBE-77269B8861EFQ38730590-1721F47C-EA03-4C02-AE1F-BBF6B512059CQ38842126-AECE83C8-B641-4ED2-86EB-B00A0A84EB9BQ38874911-80254723-9EF9-44F1-AAAF-50C2B3FA7E75Q38964798-E06D3740-0406-44A8-B123-621A9E54F2EFQ39552853-EE632804-9FEC-4A16-AA85-866E83ED39BBQ40626645-525F141E-4536-40DE-BD43-C53869066CEFQ41694140-091F9531-F050-4776-A277-307E96EC77C9Q42265633-BDFB8389-27B2-445B-8AE0-F348AED0B828Q46271291-06F92359-82E0-440E-BBA5-B57ECEBD7E83Q47112373-CD6001F4-B91E-495B-B0BA-6FE2D04A9D5FQ48176349-6328D9B3-85D8-4CB0-91D2-CC4442E0EE25Q48283444-64D219B9-939F-40CC-9DED-A70FCF657B97Q49312630-4089ED4F-AF6D-4FCE-BF48-B9262792E986
P2860
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.
@ast
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.
@en
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.
@nl
type
label
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.
@ast
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.
@en
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.
@nl
prefLabel
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.
@ast
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.
@en
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.
@nl
P2093
P1476
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.
@en
P2093
Bernhard Frankenberger
Dolores J Schendel
Elfriede Noessner
Gregor Babaryka
Kathleen Ebelt
Thomas Kirchner
Wolfgang Eisenmenger
P304
P356
10.1016/J.EJCA.2009.02.015
P577
2009-03-21T00:00:00Z